You are currently browsing:

Simple test could predict response to anthracycline chemotherapy for patients with ‘triple negative’ breast cancer

Could this be a turning point in breast cancer research? Researchers at Queen’s University Belfast have found a new biomarker that could predict the effectiveness of a common type of chemotherapy for patients with triple negative breast cancer. To read more about this exciting discovery, click the link below:

Read More

Breast cancer treatments: Current, new and emerging therapies

At the 2019 AACR Foundation Annual Meeting, researchers discussed the landscape of breast cancer treatment. Have a read of the article at the link below – the Breast Cancer Research Foundation outlines the successes, challenges and promising innovations ahead for each breast cancer subtype.

Read More

FDA approves Atezolizumab for Triple-Negative Breast Cancer

The US FDA has granted accelerated approval of a new treatment for triple-negative breast cancer, which is difficult to treat. Further trials are required, but early studies strongly suggest that patients with triple-negative breast cancer benefit from this combination treatment. For further details, click on the link below:     

Read More

Mortality rates from breast cancer in Europe predicted to fall in 2019

According to a study published in the journal, Annals of Oncology, mortality rates from breast cancer are predicted to fall across Europe in 2019 thanks to improvements in screening, early diagnosis and treatment. Breast Cancer Ireland hopes that with more research, mortality rates will continue to decrease in the coming years. For further details, please […]

Read More

Leopardstown Race Event Supporting Breast Cancer Ireland

Leopardstown Racecourse continues to support Breast Cancer Ireland by hosting their Ladies Evening this year on Friday, May 17. This is the third time this event – also supported by Microsoft – is being held in aid of Breast Cancer Ireland. The exclusive evening will feature champagne, food, entertainment, and moving speeches from keynote speakers […]

Read More